oleclumab,ceralasertib,durvalumab,olaparib,danvatirsen,trastuzumab deruxtecan,cediranib,vistusertib
merck,astrazeneca,daiichi sankyo
['hudson']
hudson #aacr23 still plenty of life-altering late-effects; infertility, seizures, neurocognitive deficits, hearing/vision loss. progress but a disparity in survival. shows data from ccss cohort. 
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.